MiniMed Posts Strong Q4 Sales Growth, Exceeds $3B Annual Revenue, Projects 10% Organic Growth for FY27
Summary
MiniMed reported strong fourth-quarter net sales of $837 million, up 16% year-over-year, contributing to a record full fiscal year 2026 revenue exceeding $3 billion, a 14% increase. The company provided a positive outlook for fiscal year 2027, forecasting approximately 10% organic revenue growth and a 16% Adjusted EBITDA margin. This strong performance follows recent product advancements, including early FDA clearance for MiniMed Flex in March and Health Canada authorization for Simplera Sync in April. New product launches like MiniMed Go in the U.S. and MiniMed Flex pre-orders starting this week, along with an expanded Abbott partnership, are expected to drive continued momentum. The results indicate robust demand and successful commercialization, especially after the significant net loss reported in the Q1 10-Q.
At the time of this announcement, MMED was trading at $11.89 on NASDAQ in the Life Sciences sector. The 52-week trading range was $10.65 to $19.05. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: PR Newswire.